Qiagen
 |
|
| Naamloze vennootschap | |
| Traded as | NASDAQ: QGEN, : QIA |
| Industry | Biotechnology |
| Founded | November 29, 1984 |
| Headquarters | Venlo, Netherlands (corporate); Hilden (near Düsseldorf), Germany (operational) |
|
Key people
|
Peer Schatz (CEO and chairman of the executive board), Prof. Dr. Manfred Karobath (Chairman of the supervisory board) |
| Revenue | US $1.337.991 billion (2016) |
| US $324.8 million (2016 adjusted, excluding restructuring charge) | |
| Profit | US $207.9 million (2016 adjusted) |
| Total assets | US $4.308.194 billion (end of December 2016) |
| Total equity | US $2.607.096 billion (end of December 2016) |
|
Number of employees
|
about 4,700 (end of December 2016) |
| Website | www |
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 25 countries.[1] Qiagen’s shares are listed at the technology-focused U.S. stock exchange Nasdaq (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Peer M. Schatz is the company’s Chief Executive Officer. The main operative headquarters are located in Hilden, Germany (near Düsseldorf).
QIAGEN is a worldwide provider of molecular sample and assay technologies. Sample technologies are used to collect samples of tissue, fluids, etc. and stabilize, extract and purify various molecules of interest such as DNA, RNA or proteins from other cellular components. Assay technologies are then used to amplify (multiply) and enrich this small amount of isolated material to make it visible, readable and ready for interpretation. The separation and purification of genetic information is a basic precondition for further application or analysis.
Qiagen provides molecular technologies offered as kits with open or specific target analytes. According to Qiagen, the company’s current portfolio covers more than 500 products and more than 2,000 patents and licenses.
In 2014, Qiagen entered into a supply agreement with Trinean for the manufacture of a Qiagen-branded "micro-volume" spectrophotometer, to be sold under the name "QIAxpert".
Until the mid-2000s, the company was mainly a provider of sample technologies for the academic research market. Today, Qiagen’s product portfolio includes sample and assay technologies, specific automation solutions, and a bioinformatics analysis portfolio in the following 4 markets:
Molecular diagnostics detect the nucleic acids (DNA and RNA) of target diseases or pathogens in samples such as blood or tissue. These procedures can help to detect viruses and bacteria more rapidly and with greater sensitivity and specificity than other methods such as bacterial culture or immunodiagnostics. Molecular diagnostics are also used to analyze individual patient's genomic information to further classify certain diseases and to determine the most appropriate treatment. Qiagen’s portfolio in molecular diagnostics covers various applications which the company divides into three main segments:
...
Wikipedia